神经母细胞瘤液体活检的进展
Advances in liquid biopsy in neuroblastoma.
作者信息
Zhuo Zhenjian, Lin Lei, Miao Lei, Li Meng, He Jing
机构信息
Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China.
Laboratory Animal Center, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
出版信息
Fundam Res. 2022 Aug 17;2(6):903-917. doi: 10.1016/j.fmre.2022.08.005. eCollection 2022 Nov.
Even with intensive treatment of high-risk neuroblastoma (NB) patients, half of high-risk NB patients still relapse. New therapies targeting the biological characteristics of NB have important clinical value for the personalized treatment of NB. However, the current biological markers for NB are mainly analyzed by tissue biopsy. In recent years, circulating biomarkers of NB based on liquid biopsy have attracted more and more attention. This review summarizes the analytes and methods for liquid biopsy of NB. We focus on the application of liquid biopsy in the diagnosis, prognosis assessment, and monitoring of NB. Finally, we discuss the prospects and challenges of liquid biopsy in NB.
即使对高危神经母细胞瘤（NB）患者进行强化治疗，仍有一半的高危NB患者会复发。针对NB生物学特性的新疗法对NB的个性化治疗具有重要临床价值。然而，目前NB的生物学标志物主要通过组织活检进行分析。近年来，基于液体活检的NB循环生物标志物越来越受到关注。本文综述了NB液体活检的分析物和方法。我们重点关注液体活检在NB诊断、预后评估和监测中的应用。最后，我们讨论了液体活检在NB中的前景和挑战。
Zotero 插件